Regeneron Pharmaceuticals, Inc.
Financials
Valuation Metrics
Regeneron Pharmaceuticals, Inc.'s Market Cap is $100.76B. At end of 2025 it was $79.33B. Ranked #200 of 3,116 in US market (top 6%), #60 of 1,472 on NASDAQ (top 4%), #16 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $100.76B | US#200/3,116 Sec#16/265 |
| Revenue | $15.53B | US#405/3,116 Sec#16/265 |
| Net Income | $4.33B | US#182/3,116 Sec#13/265 |
| Total Assets | $41.73B | US#370/3,116 Sec#16/265 |
| Net Assets | $31.71B | US#148/3,116 Sec#10/265 |
| Employees | 15,410 | US#659/3,116 Sec#21/265 |
| Value | ||
| P/E | 23.28x | US#1,095/3,116 Sec#33/265 |
| P/B | 3.18x | US#1,630/3,116 Sec#84/265 |
| P/S | 6.49x | US#2,360/3,116 Sec#85/265 |
| EV/EBITDA | 17.44x | US#1,466/3,116 Sec#40/265 |
| FCF Yield | 3.50% | US#1,568/3,116 Sec#48/265 |
| Profitability | ||
| ROE | 13.65% | US#992/3,116 Sec#41/265 |
| ROA | 10.37% | US#461/3,116 Sec#35/265 |
| Op. Margin | 25.56% | US#650/3,116 Sec#33/265 |
| Revenue Growth | 9.29% | US#1,310/3,116 Sec#99/265 |
| Earnings Growth | -2.91% | US#1,333/3,116 Sec#34/265 |
| Financial Health | ||
| Debt Ratio | 31.59% | US#355/3,116 Sec#109/265 |
| Total Debt | $1.99B | US#1,170/3,116 Sec#34/265 |
| FCF | $3.52B | US#227/3,116 Sec#16/265 |
| Cash | $2.46B | US#346/3,116 Sec#19/265 |
| Current Ratio | 3.34x | US#681/3,116 Sec#178/265 |
| Net Debt/EBITDA | -0.08x | US#544/3,116 Sec#32/265 |
| Dividend | ||
| Div. Yield | 0.38% | US#1,551/3,116 Sec#25/265 |
| Performance | ||
| 1Y Return | 47.81% | US#1,024/3,116 Sec#105/265 |
| 1M Return | 30.72% | US#836/3,116 Sec#61/265 |
| From 52W High | -1.33% | US#453/3,116 Sec#35/265 |
| 1Y MDD | -25.96% | US#1,012/3,116 Sec#46/265 |
| Trading | ||
| Volume | 1,473,268 shares | US#1,853/3,116 Sec#184/265 |
| Trading Value | $1.41B | US#206/3,116 Sec#10/265 |
| Per Share | ||
| EPS | $41.29 | US#24/3,116 Sec#1/265 |
| BPS | $302.47 | US#13/3,116 Sec#1/265 |
Company Info
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.